Prime Medicine (PRME) Times Interest Earned (2021 - 2026)
Prime Medicine's (PRME) quarterly Times Interest Earned came in at -$0.28 in Q1 2026, down 8.13% YoY from -$0.31 in Q1 2025, and up 100.0% on a QoQ basis from -$16202.7 in Q4 2025.
Prime Medicine (PRME) Times Interest Earned (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Times Interest Earned data on file, last reported at -$0.28 in Q1 2026.
- Quarterly Times Interest Earned fell 8.13% year-over-year to -$0.28 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.15 (down 11.89% YoY) and the FY2025 annual result came in at -$69450.0, down 6166590.2% from the prior year.
- Times Interest Earned rose to -$0.28 in Q1 2026, from -$16202.7 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.24 in Q1 2024 to a low of -$16202.7 in Q4 2025.
- A 5-year average of -$1103.4 and a median of -$0.57 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned soared 99.11% — and 2025, when it slumped 6586817.84%.
- Tracing PRME's Times Interest Earned over 5 years: stood at -$0.62 in 2022, then gained by 8.36% to -$0.57 in 2023, then surged by 56.89% to -$0.25 in 2024, then tumbled by 6586817.84% to -$16202.7 in 2025, then jumped by 100.0% to -$0.28 in 2026.
- The last three Times Interest Earned figures came in at -$0.28 (Q1 2026), -$16202.7 (Q4 2025), and -$0.75 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | -0.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.25 |
| Mar 31, 2026 | -0.28 |
| Dec 31, 2025 | -16,202.67 |
| Sep 30, 2025 | -0.75 |
| Jun 30, 2025 | -0.27 |
| Mar 31, 2025 | -0.26 |
| Dec 31, 2024 | -0.25 |
| Sep 30, 2024 | -0.26 |
| Jun 30, 2024 | -0.27 |
| Mar 31, 2024 | -0.24 |
| Dec 31, 2023 | -0.57 |
| Sep 30, 2023 | -2.82 |
| Jun 30, 2023 | -1.64 |
| Mar 31, 2023 | -23.79 |
| Dec 31, 2022 | -0.62 |
| Sep 30, 2022 | -316.55 |
| Dec 31, 2021 | -2.38 |